Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | -12.50% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.72 | N/A | -12.50% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current market conditions. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs despite the challenges.
Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.63% decline in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's short-term outlook. Management's cautious tone suggests they are navigating challenges while focusing on their clinical programs.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEMPRA
May 4, 2020